Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT04506619
Other study ID # SHP607-203
Secondary ID 2020-002726-84
Status Terminated
Phase
First received
Last updated
Start date September 9, 2020
Est. completion date August 5, 2022

Study information

Verified date April 2022
Source Oak Hill Bio Ltd
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The purpose of this study is to evaluate long-term safety and efficacy outcomes following previously administered short-term exposure to SHP607, as compared to a standard neonatal care group.


Description:

In this long-term follow-up study, participants who enrolled in SHP607-202 (NCT03253263) will be followed from 12 months corrected age (CA) through 60 months CA. Participants will not receive any investigational product in this study.


Recruitment information / eligibility

Status Terminated
Enrollment 26
Est. completion date August 5, 2022
Est. primary completion date August 5, 2022
Accepts healthy volunteers No
Gender All
Age group 12 Months to 24 Months
Eligibility Inclusion Criteria: - Participants who were randomized into Study SHP607-202 (NCT03253263). Participants who were randomized, but did not complete Study SHP607-202 (NCT03253263) must be at least 12 months CA. - Written informed consents (and assents, if applicable) must be signed and dated by the participant's parent(s)/legally authorized representative(s) prior to any study-related procedures. The informed consent and any assents for underage parents must be approved by the institutional review board (IRB)/independent ethics committee (IEC). Exclusion Criteria: - Participants are excluded from the study if the participant or participant's parent(s)/legally authorized representative(s) is/are unable to comply with the protocol or is/are unlikely to be available for long-term follow-up as determined by the investigator.

Study Design


Intervention

Other:
No Intervention
This is a non-interventional study.

Locations

Country Name City State
Italy Azienda Ospedaliera Universitaria Careggi Firenze
Italy Istituto G Gaslini Ospedale Pediatrico IRCCS - INCIPIT - PIN Genova
Italy Presidio Ospedaliero Di Treviso Ca' Foncello Treviso
United Kingdom Ashford and St. Peter's Hospitals NHS Trust - St. Peter*s Hospital Chertsey Surrey
United States University of Mississippi Medical Center Jackson Mississippi
United States University of Mississippi Medical Center Jackson Mississippi
United States Robert Wood Johnson Medical School New Brunswick New Jersey
United States Memorial Hospital of South Bend South Bend Indiana

Sponsors (1)

Lead Sponsor Collaborator
Oak Hill Bio Ltd

Countries where clinical trial is conducted

United States,  Italy,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Emergency Room Visits Number of emergency room visits associated with a respiratory diagnosis will be reported. 12 months CA through 60 months CA
Primary Number of Hospitalizations Number of hospitalizations associated with a respiratory diagnosis will be reported. 12 months CA through 60 months CA
Primary Incidence of Signs and Symptoms of Respiratory Disease Incidence of signs and symptoms of respiratory disease (yes/no) is assessed by recording episodes of wheezing, coughing, and respiratory medication. 12 months CA through 60 months CA
Primary Number of Days of Respiratory Medication Use Number of days of respiratory medication use (for example, bronchodilators, steroids, leukotriene inhibitors, diuretics) will be reported. 12 months CA through 60 months CA
Primary Total Number of Days on Home Respiratory Technology use Total number of days on home respiratory technology use (for example, home oxygen, continuous positive airway pressure [CPAP], tracheostomy) will be reported. 12 months CA through 60 months CA
Primary Number of Participants With Adverse Events (AEs) An adverse event (AE) is any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. 12 months CA through 60 months CA
Secondary Growth Parameters: Body Weight Body weight is measured in kilograms (kg) without shoes and with light clothing using a calibrated scale. At 12, 24, and 60 months CA
Secondary Growth Parameters: Body Length Body length is a supine measurement from the top of the head to the sole of the foot with the participant lying on the back with hips and knees extended. At 12 and 24 months CA
Secondary Growth Parameters: Height Height is a measure of participant from head to foot (standing measure). A stadiometer should be utilized for measurement of height. At 60 months CA
Secondary Growth parameters: Head circumference Head circumference or occipital frontal circumference is measured over the occiput and just above the supraorbital ridge, which is the largest circumference of the head. At 12 and 24 months CA
Secondary Physical Development as Assessed by Physical Examination Physical examinations will include a review of the participant's general appearance. At 12, 24, and 60 months CA
Secondary Physical Development as Assessed by Neurological Examination for Assessment of Cerebral Palsy Neurological examination for the diagnosis of cerebral palsy (CP) will be conducted. Neurologic examinations for the diagnosis of CP will be conducted by physicians including assessment of motor function, strength and development, muscle tone, and postural and movement abnormalities. At 12, 24, and 60 months CA
Secondary Physical Development as Assessed by Visual Acuity Visual acuity is a measure of how well a participant sees at different distances. It will be categorized as the following: normal (measurable acuity greater than or equal to [>=] 20/40); below normal (20/200 less than or equal to [<=] measurable acuity <20/40); poor (measurable acuity <=20/200); blind/low vision (only the ability to detect the 2.2 centimeter [cm] wide stripes on the low-vision Teller acuity card and at any location in the visual field). At 12, 24, and 60 months CA
Secondary Cognitive Development Assessed by Bayley Scales of Infant and Toddler Development (BSID-III) The BSID-III will be used to assess cognitive, motor, and language skills, and is applicable to children aged 1-42 months. The BSID-III is an assessment tool designed to measure a young child's skills in the 3 core areas of development: cognitive, language, and motor. There are 5 subscales, the cognitive subscale (Score range: 55-145) stands alone while the 2 language subscales (expressive and receptive) combine to make a total language score (Range: 47-153) and the 2 motor subtests (fine and gross motor) form a combined motor scale (Range: 46-154). A positive value indicates improvement. At 24 months CA
Secondary Cognitive Development Quotient Assessed by Kyoto Scale of Psychological Development (KSPD) KSPD is a alternative scale to the BSID and used to assess cognitive, motor, and language skills at Japan sites only. The KSPD is a validated neurodevelopmental outcome assessment that is standardized for Japanese children and has been evaluated in comparison to BSID in the assessment of developmental characteristics of very low birth weight Japanese infants. The KSPD is designed to measure a young child's skills in three domains of development: Cognitive-Adaptive (non-verbal reasoning or visuospatial perception), Language-Social (interpersonal relationships, socialization, verbal abilities), and Postural-Motor (fine and gross motor functions). The scale consists of 328 items covering a Cognitive-Adaptive area, Language-Social area, and Postural-Motor area. For each of the three areas, a sum score is converted to a Developmental Quotient (dividing the developmental age by the chronological age and then multiplying the quotient by 100). A positive value indicates improvement. At 24 months CA
Secondary Cognitive Development Assessed by Wechsler Preschool and Primary Scale of Intelligence (WPPSI) The WPPSI is a measure of general cognitive development in children that has components of both verbal and non-verbal tasks. It is applicable to preschoolers and young children aged 2 years +6 months to 7 years +7 months, and is a direct assessment of a child's cognitive skills. The standard score For the WPPSI ranges from Below 70 (extremely low) to above 130 (very superior). At 60 months CA
Secondary Gross Motor Function Assessed by Gross Motor Function Measure-88 (GMFM-88) The GMFM-88 item scores is used to calculate a domain-specific percent score for each of the 5 GMFM-88 dimensions, which are the following: Lying and rolling; Sitting; Crawling and kneeling; Standing; Walking, running, and jumping. Each of the 88 items is rated on a 4-point scale: 0=does not initiate; 1=initiates; 2=partially completes; and 3=completes. The GMFM-88 total scores range from 0% (no mobility) to a score of 100%. The test is considered to be appropriate for children whose motor skills are at or below those of a 5-year-old child without any motor disability. The GMFM-88 will be administered at 24 months CA. GMFM-88 Sections D (Standing) and E (Walking, Running and Jumping) only will be administered at 5 years CA. At 24 and 60 months CA
Secondary Childhood Behavior Assessed by Vineland Adaptive Behavior Scales (VABS-III) The VABS-III test measures adaptive behaviors, including the ability to cope with environmental changes, to learn new everyday skills, and to demonstrate independence. This test measures the following 4 key domains: communication, daily living skills, socialization, and motor skills. The score ranges from 20 to 140 on which higher scores indicate a higher level of better behavior. At 24 and 60 months CA
Secondary Childhood Behavior Assessed by Attention-Deficit/Hyperactivity Disorder Rating Scale (ADHD-RS-V) The ADHD-RS-V measures the behaviors of children with Attention-Deficit/Hyperactivity Disorder (ADHD). It consists of 18 items designed to reflect current symptomatology of ADHD based on DSM-V criteria. Each item is scored from a range of 0 (reflecting no symptoms) to 3 (reflecting severe symptoms) with total scores ranging from 0-54. The 18 items are grouped into 2 subscales: hyperactivity-impulsivity (even numbered items 2-18) and inattention ("inattentiveness") (odd numbered items 1-17). At 60 months CA
Secondary Childhood Behavior Assessed by Social Communication Questionnaire (SCQ) The SCQ is a brief instrument that helps evaluate communication skills and social functioning in children that can be used for screening for autism or autism spectrum disorders (ASD) in the general population. The score ranges from 0 to 39, with a cut off of greater than (>) 15 indicating ASD. At 60 months CA
Secondary Health Related Quality of Life (HRQoL) Assessed by the Pediatric Quality of Life Inventory (PedsQL) Scales HRQoL will be assessed via the validated Pediatric Quality of Life Inventory (PedsQL) Scales appropriate for the child's age of development. The following scales will be used in this study: Infant Scale for ages 13-24 months (45 Items); Toddler Scale for 2-4 years of age (21 Items); Young Child Scale for 5-7 years of age (23 Items). Scores are transformed to a 0 to 100 scale. Higher scores indicate better quality of life. At 24, 36, 48, and 60 months CA
Secondary Health Status Measured by the Health Utilities Index 2/3 The Health Utilities Index (HUI) is a family of generic health profiles and preference-based systems used for measuring health status, reporting HRQoL, and producing utility scores. The HUI 2/3 system contains a number of attributes/domains to classify the level of health status. Each attribute or domain (eg, mobility, cognition, emotion or pain) is rated on a 5-point ordinal scale to indicate the severity level, ranging from 1-5 (higher numbers indicating a more severe level). At 60 months CA
Secondary Healthcare Resource Utilization Healthcare resource utilization is measured by the number of in-patient and outpatient visits, including emergency room visits and visits to specialists. 12 months CA through 60 months CA
Secondary Number of Participants With Targeted Medical Events and Fatal Serious Adverse Events (SAEs) Targeted medical events are intracranial hypertension, any abnormality of glucose metabolism (eg, hypoglycemia, hyperglycemia, and diabetes), tonsillar hypertrophy (based on tonsil examination [part of the physical examination]), and increased cardiac size. A serious adverse event (SAE) is defined as an untoward medical occurrence that at any dose meets one or more of the following criteria: outcome is fatal/results in death, is life-threatening, requires inpatient hospitalization or results in prolongation of an existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is a medically important event. 12 months CA through 60 months CA
See also
  Status Clinical Trial Phase
Completed NCT04936477 - Ventilation-perfusion (V/Q) Ratio and Alveolar Surface Area in Preterm Infants N/A
Recruiting NCT05285345 - Implementation of a Consensus-Based Discharge Protocol for Preterm Infants With Lung Disease
Completed NCT03649932 - Enteral L Citrulline Supplementation in Preterm Infants - Safety, Efficacy and Dosing Phase 1
Terminated NCT02524249 - Early Versus Late Caffeine for ELBW Newborns N/A
Completed NCT02249143 - Duration of Continuous Positive Airway Pressure and Pulmonary Function Testing in Preterm Infants N/A
Active, not recruiting NCT01632475 - Follow-Up Study of Safety and Efficacy of Pneumostem® in Premature Infants With Bronchopulmonary Dysplasia
Completed NCT01460576 - Improving Prematurity-Related Respiratory Outcomes at Vanderbilt N/A
Completed NCT00419588 - Growth of Airways and Lung Tissues in Premature and Healthy Infants
Unknown status NCT00254176 - Cysteine Supplementation in Critically Ill Neonates Phase 2/Phase 3
Completed NCT00208039 - Pilot Trial of Surfactant Booster Prophylaxis For Ventilated Preterm Neonates N/A
Completed NCT00319956 - Trial II of Lung Protection With Azithromycin in the Preterm Infant Phase 2
Completed NCT00006401 - Inhaled Nitric Oxide for Preventing Chronic Lung Disease in Premature Infants Phase 3
Terminated NCT05030012 - Maintaining Optimal HVNI Delivery Using Automatic Titration of Oxygen in Preterm Infants N/A
Completed NCT00006058 - Study of the Pathobiology of Bronchopulmonary Dysplasia in Newborns N/A
Completed NCT00005376 - Premature Birth and Its Sequelae in Women N/A
Completed NCT00011362 - Dexamethasone Therapy in VLBW Infants at Risk of CLD Phase 3
Completed NCT00004805 - Study of the Effect of Four Methods of Cardiopulmonary Resuscitation Instruction on Psychosocial Response of Parents With Infants at Risk of Sudden Death N/A
Completed NCT05152316 - The Baby Lung Study
Recruiting NCT04821453 - NAVA vs. CMV Crossover in Severe BPD N/A
Active, not recruiting NCT04662151 - A Clinical Safety Study of AT-100 (rhSP-D) in Preterm Neonates at High Risk for Bronchopulmonary Dysplasia (BPD) Phase 1